A pan-neurodegeneration atlas built from multilayer, deep proteomics of 2,279 brain samples across 6 major diseases integrates whole proteome, detergent-insoluble proteome, and posttranslational modifications to enable intra- and inter-disease comparisons to reveal disease-specific subtypes and dysregulated pathways, while identifying shared changes such as GPNMB upregulation and NPTX2 downregulation.

Human pancreatic cancer cells sense specific components of the ECM to fine-tune their autophagy flux levels, conferring the ability to coordinate proliferation, survival, and responsiveness to chemotherapy. Targeting ECM sensing may turn this ability into a therapeutic opportunity.